CAR T cell treatment for CD70-positive newly diagnosed glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a customized immune-cell treatment (CAR T cells) for adults with newly diagnosed glioblastoma (GBM) whose tumors have enough CD70 protein. If you qualify, the goal is to see whether this treatment can better control the cancer by targeting it in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have newly diagnosed GBM (not a previously treated brain tumor) confirmed by pathology or tumor testing
- Tumor must be located in the upper part of the brain (supratentorial area)
- Tumor tissue must be CD70-positive, meaning at least 5% of cells show low-to-moderate CD70 levels (1+ or higher)
- Be healthy enough for treatment: Karnofsky score over 70% and blood counts/kidney/liver tests within set limits
- Be able and willing to sign consent (or have a legal representative sign), and avoid pregnancy during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
This Phase 1 trial tests a new type of immune cell therapy (CAR T cells) designed to fight cancers that have spread to the brain. The cells are engineered to recognize and attack cancer cells that express a protein called CD70, and may help patients whose cancer has come back or progressed.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.